Innovative Science is the Curative Agent for Treating Viral Infections
The active ingredient, interferon α2b, is absorbed directly into the respiratory tract via an inhaler. Viral respiratory diseases such as COVID-19, influenza, encephalitis and many others can thus be combated in the outbreak phase. Severe courses can be successfully prevented.
MM-003 Prevents future pandemics Most viruses enter the body through the respiratory tract. MM-003 can be made available in pharmacies and doctors’ offices, is easy to use and works efficiently without side effects.
The company’s proprietary interferon α2b cream formulation is used to treat malignancies caused by the human papillomavirus (HPV), which can lead to cervical cancer.
Cervical cancer is the fourth most common cancer in women worldwide, with an estimated 604,000 new cases and 342,000 deaths in 2020.
This special cream formulation allows treatment through the skin or mucosa without unwanted side effects. Unlike current treatments, which are all invasive, MM-001 can be self-applied by the patient and is very well tolerated.
♦ Inhalation applies directly to the lungs, halting viral replication ♦ Potentially overcomes block restoring anti viral activity ♦ May help restore initial immune response to COVID-19 ♦ Has promise as first-line treatment for COVID-19, its variants and other respiratory viruses (MERs, SARs) ♦ MM-003 has potential to be used as prophylaxis/prevention ♦ Potential prevention of L/T damage to lung, heart, kidney, & brain
♦ MM-003 is being developed as a novel interferon inhalation formulation ♦ IFNa2b has been used to treat COVID-19 in China ♦ MM-003 early treatment approach may prevent virus progression to severe disease and need for hospitalization ♦ MM-003 has promise to be first-line treatment for COVID-19, its variants and other respiratory viruses (MERs, SARs) ♦ MM-003 has potential to be used as prophylaxis/prevention
♦ MM-003 is manufactured from a novel IFNa2b recombinant clone. The IFNa2b is “isoform” free.
♦ Patent pending proprietary MM-003 formulation improves stability of the IFNa2b and is adapted to inhalation delivery
♦ Additional formulations also are covered
♦ MedMelior’s MM-003 patent application covers potential treatment of COVID-19 (and all other respiratory tract viral infections)
♦ MedMelior’s MM-003 patent application also describes potential prevention/prophylaxis against COVID-19 (and all other respiratory tract viral infections)
♦ MedMelior‘s proprietary interferon α2b cream formulation
♦ Patient self-administered topical cream
♦ Delivery system prevents leakage allowing for prolonged coating
♦ Completed Phase 1 and 2 clinical trials shows active and safe cream
♦ No systemic IFNα2b detected, no safety/tolerability concerns
♦ A multi billion-dollar market ♦ An unaddressed and underserved market ♦ Number of HPV cases are still significant ♦ Currently, no non-surgical treatments in the market-place ♦ Dermal delivery systems today cause irritation and or damage to the skin
